Claims
- 1. A compound which is crystalline 3-(4hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (+) L-hydrogen tartrate.
- 2. A pharmaceutical composition comprising the compound according to claim 1 together with a pharmaceutically acceptable carrier or diluent.
- 3. The pharmaceutical composition according to claim 2 in the form of an oral dosage unit containing from 1 to 200 mg of the compound.
- 4. A method of treating cognitive dysfunction caused by Alzheimer's disease in a mammal comprising administering an effective amount of the compound according to claim 1.
- 5. A method of treating cognitive dysfunction caused by Alzheimer's disease in a mammal comprising administering a pharmaceutical composition according to claim 2.
Parent Case Info
This application is a continuation of application Ser. No. 08/526,605, filed Sep. 11, 1995, now abandoned, which is a continuation of application Ser. No. 08/285,600, filed Aug. 3, 1994, now abandoned, which is a continuation of application Ser. No. 08/072,572, filed Jun. 4, 1993, now abandoned, the contents of which are incorporated herein by reference.
US Referenced Citations (4)
Non-Patent Literature Citations (4)
Entry |
Sauerberg et al., J. Med. Chem., vol. 35, pp. 2274-2283 (1992). |
Berger et al "Pharmaceutical Salts" J. Pharm. Sci. 66(1) 1-19 (1977). |
Hamilton et al., Journal of Chromatography, 613 (1993) pp. 365-270. |
Levine et al., Life Science, vol. 52, Nos. 5/6 (1993). |
Continuations (3)
|
Number |
Date |
Country |
Parent |
526605 |
Sep 1995 |
|
Parent |
285600 |
Aug 1994 |
|
Parent |
72572 |
Jun 1993 |
|